. Author manuscript; available in PMC: 2016 Oct 1.

Published in final edited form as: Transl Res. 2015 Mar 16;166(4):384–398. doi: 10.1016/j.trsl.2015.03.002

Table 1.

	1	2	3
	P_alb FSGS serum^a Untreated	P_alb FSGS Serum + JAK2 Inhibitor^a,^b (percent decrease, 1–2)	P_alb FSGS Serum + STAT3 Inhibitor^a,^c (percent decrease, 1–3)
Recurr (M)	0.75	0.44 (41)	0.32 (57)
Recurr (M)	0.82	0.42 (49)	0.35 (57)
Recurr (M)	0.77	0.42 (46)	0.36 (53)
2^nd Recurr (M)	0.69	0.50 (28)	0.41 (43)
Recurr (M)	0.88	0.42 (52)	0.47 (47)
Mean	0.78	0.44 (43)	0.38 (51)
SD	0.06	0.031	0.0526
SEM	0.028	0.0138	0.0235
P value 1 vs. 2 or 3		<0.001	<0.001

Each value represents the mean of 5 glomeruli observed.

Glomeruli were incubated with JAK2 inhibitor BMS 911543 (5µM) for 15 minutes followed by addition of FSGS serum and incubation for 15 minutes at 37°C.

Glomeruli were incubated with STAT3 inhibitor Stattic (1µM) for 15 minutes followed by addition of FSGS serum and incubation for 15 minutes at 37°C.

Abbreviations: M- Male; Recurr- Recurrence

Control P_alb 0.003±0.041